QNRX: Gunggung dhuwit awis saben saham Quoin Pharmaceuticals Ltd.

Lambang korporat lan logo Quoin Pharmaceuticals Ltd (QNRX)

Quoin Pharmaceuticals' focus on patents within the orphan dermatology niche drives its financial dynamics. Cash per share visualizes current capital, where 6.91 reflects the latest value of the metric. Diversified European and US manufacturing outsourcing reduces logistical risks, although high development costs and dependence on clinical outcomes create certain pressure on balance sheet liquidity.

QNRX (quoinpharma.com) riwayat Dhuwit awis saben saham saka 04.07.2022 nganti 21.11.2026

Rincian analitis perusahaan Quoin Pharmaceuticals

Analisis komprehensif perusahaan:QNRX Quoin Pharmaceuticals Ltd.
Barang utama Quoin Pharmaceuticals

Cash per share determines the level of direct liquidity available to each security holder. Daily recalculations eliminate accounting lags, capturing real-time changes in the volume of free cash. By analyzing the cash per share figure, an investor assesses protection against liquidity gaps. Growth in this metric is critically important for Quoin Pharmaceuticals (QNRX), as it ensures the funding for the development of drugs to treat rare skin pathologies.